Nicholas Investment Partners LP Takes $7.60 Million Position in Palvella Therapeutics, Inc. $PVLA

Nicholas Investment Partners LP acquired a new position in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 49,718 shares of the company’s stock, valued at approximately $7,598,000. Nicholas Investment Partners LP owned 0.35% of Palvella Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Legal & General Group Plc bought a new stake in Palvella Therapeutics during the second quarter valued at $1,222,000. The Manufacturers Life Insurance Company bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $2,376,000. Northwestern Mutual Wealth Management Co. bought a new position in shares of Palvella Therapeutics in the 2nd quarter worth about $35,000. Quantbot Technologies LP acquired a new position in shares of Palvella Therapeutics in the 2nd quarter valued at about $71,000. Finally, Blue Owl Capital Holdings LP bought a new stake in shares of Palvella Therapeutics during the 2nd quarter valued at about $5,541,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on PVLA shares. HC Wainwright reaffirmed a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Truist Financial set a $207.00 price target on Palvella Therapeutics in a research note on Wednesday, August 5th. Stephens restated an “overweight” rating and set a $220.00 price target on shares of Palvella Therapeutics in a report on Thursday, May 21st. Chardan Capital raised shares of Palvella Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $232.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Palvella Therapeutics has an average rating of “Buy” and an average target price of $209.14.

Palvella Therapeutics Price Performance

PVLA stock opened at $145.75 on Tuesday. The company’s 50-day moving average is $142.93 and its 200-day moving average is $125.24. The stock has a market capitalization of $2.10 billion, a PE ratio of -30.18 and a beta of -0.17. Palvella Therapeutics, Inc. has a 1 year low of $49.13 and a 1 year high of $161.38.

Palvella Therapeutics (NASDAQ:PVLA) last issued its earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($0.35). On average, analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total value of $654,807.42. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company’s stock, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 17.20% of the company’s stock.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.